Figure 2.
Dengue neutralizing antibody GMTs (95% CI) in participants aged <9 y by baseline dengue status, region and study. PD3, post-dose 3; sero1–4, serotype 1–4.
Dengue neutralizing antibody GMTs (95% CI) in participants aged <9 y by baseline dengue status, region and study. PD3, post-dose 3; sero1–4, serotype 1–4.